Search results
Coexistence of psoriatic arthritis, atopic dermatitis may offer treatment insights
Medical Xpress· 14 hours agoPsoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both...
It Took Me Years to Find the Right Psoriatic Arthritis Medication
Verywell Health via Yahoo News· 15 hours agoAfter being diagnosed with psoriatic arthritis in 2016, it took LB Herbert years to find a psoriatic...
Sketchy stem-cell treatments in Mexico led to drug-resistant infections
Live Science via Yahoo News· 1 day agoTwo similar cases involved men in their 60s — one from Arizona and one from Colorado. The Arizona...
Stem cell treatments in Mexico linked to drug-resistant meningitis, joint infections - UPI.com
UPI· 5 days agoThe cases outlined in the new report began in late 2022, when a Colorado woman in her 30s showed up...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 6 days ago“Our top priority is executing on our strategy to accelerate the development and delivery of transformative medicines for patients, and we are confident that we can accomplish this mission while ...
Stelara interactions: Other medications, alcohol, and more
Medical News Today· 5 days agoStelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions....
Amgen Inc. (AMGN) To Go Ex-Dividend on May 16th
ETF DAILY NEWS· 21 hours agoAmgen Inc. (NASDAQ:AMGN – Get Free Report) announced a quarterly dividend on Wednesday, March 6th, RTT News reports. This represents a $9.00 annualized dividend and a dividend yield of 2.92% ...
Higher NSAID Dose Raises CVD Risk in Ankylosing Spondylitis
Medscape· 5 days agoNSAIDs, the primary pain management therapy for AS, increased the risk for vascular events and...
Zacks Research Comments on Bristol-Myers Squibb’s FY2024 Earnings (NYSE:BMY)
ETF DAILY NEWS· 1 day agoBristol-Myers Squibb (NYSE:BMY – Free Report) – Equities research analysts at Zacks Research issued their FY2024 earnings estimates for shares of Bristol-Myers Squibb in a report issued on Thursday ...
Brokerages Set Acelyrin, Inc. (NASDAQ:SLRN) Price Target at $23.67
ETF DAILY NEWS· 3 days agoShares of Acelyrin, Inc. (NASDAQ:SLRN – Get Free Report) have earned an average rating of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat.com ...
